SCHEMBL4156639

SCHEMBL4156639

Clc1ccc(Nc2cncc(Br)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.54
KCNH2 Q12809 2/20 0.54
SCN5A Q14524 2/20 0.54
CHRNB4 P30926 1/20 0.48
CHRNA3 P32297 1/20 0.48
XDH P47989 1/20 0.46
SLC22A12 Q96S37 1/20 0.46
LMNA P02545 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GLA P06280 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
EGFR P00533 1/20 0.42
IDO1 P14902 1/20 0.40
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
HDAC3 O15379 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29707607 1.00 SCN9A (0.54) SCN9AKCNH2SCN5ACHRNB4CHRNA3
SCHEMBL28824302 0.81 CHRNB4 (0.48) SCN9AKCNH2SCN5ACHRNB4CHRNA3
SCHEMBL30494419 0.81 CHRNB4 (0.48) SCN9AKCNH2SCN5ACHRNB4CHRNA3
SCHEMBL26465213 0.81 CHRNB4 (0.48) SCN9AKCNH2SCN5ACHRNB4CHRNA3
SCHEMBL4147660 0.81 HSD17B10 (0.48) CHRNB4CHRNA3XDHSLC22A12LMNA
SCHEMBL29707605 0.81 CHRNB4 (0.51) CHRNB4CHRNA3XDHSLC22A12LMNA
SCHEMBL28949368 0.81 CHRNB4 (0.51) CHRNB4CHRNA3XDHSLC22A12LMNA
SCHEMBL2821463 0.77 RAB9A (0.57) SCN9AKCNH2SCN5ACHRNB4CHRNA3
SCHEMBL28824305 0.77 SLC22A12 (0.49) CHRNB4CHRNA3XDHSLC22A12MEN1
SCHEMBL29707609 0.77 SLC22A12 (0.49) CHRNB4CHRNA3XDHSLC22A12MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163515-A1 Compounds Which Bind to the Active Site of Protein Kinase Enzymes BIOFOCUS DISCOVERY LTD. 2009-06-25 US disclosed
US-20090163515-A1 Compounds Which Bind to the Active Site of Protein Kinase Enzymes BIOFOCUS DISCOVERY LTD. 2009-06-25 US disclosed
US-20090163515-A1 Compounds Which Bind to the Active Site of Protein Kinase Enzymes BIOFOCUS DISCOVERY LTD. 2009-06-25 US disclosed
WO-2006072792-A2 COMPOUNDS WHICH BIND TO THE ACTIVE SITE OF PROTEIN KINASE ENZYMES GALAPAGOS NV (BE) 2006-07-13 WO disclosed
EP-1644365-A2 PYRAZINE AND PYRIDINE DERIVATIVES AS RHO KINASE INHIBITORS Biofocus Discovery Ltd (GB) 2006-04-12 EP disclosed
WO-2005003101-A2 PYRAZINE AND PYRIDINE DERIVATIVES AS RHO KINASE INHIBITORS BIOFOCUS DISCOVERY LIMITED (GB) 2005-01-13 WO disclosed
WO-2004085409-A2 COMPOUNDS AND LIBRARIES OF PYRIDINES, PYRAZINES, IMIDAZO[1,2-A]PYRAZINES AND 1H-IMIDAZO[4,5-B]PYRAZIN-2-ONES AND FIRST AND SECOND MEDICAL USES THEREOF BIOFOCUS DISCOVERY LTD (GB) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163515-A1 Compounds Which Bind to the Active Site of Protein Kinase Enzymes ROCK1, ROCK2, CIT SCN9A 4461/4885KCNH2 2003/4885SCN5A 3596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.